Deneysel diyabet modelinde Phoenixin-14'ün etkilerinin araştırılması
Küçük Resim Yok
Tarih
2025
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Diyabet, insülin üretimi ve kullanımındaki bozulmalarla karakterize bir hastalık olup, kronik hiperglisemi sonucu periferik sinirlerde hasar gelişerek diyabetik nöropatiye (DN) yol açmaktadır. Bu çalışmada, bir nöropeptid olan Phoenixin-14 (PNX-14)'ün DN modellerindeki etkinliği değerlendirildi. Materyal ve Metot: 40 adet Balb-c ırkı erkek fare kontrol, DN, DN+PNX-14/50 ve DN+PNX-14/100 olmak üzere 4 gruba ayrıldı (n=10). Kontrol dışındaki gruplara intraperitonal olarak tek doz streptozotosin (150mg/kg) uygulanarak 21 gün DN modeli oluşumu beklenildi. Kontrol grubuna bir uygulama yapılmazken, DN grubuna serum fizyolojik, DN+PNX-14/50 ve DN+PNX-14/100 gruplarına ise sırasıyla 50 ve 100µg/kg dozlarında PNX-14, intraperitonal olarak 15 gün süresince uygulandı. Bu süre boyunca farelerde nosiseptif davranış ölçümleri (hot plate, tail flick, von Frey) gerçekleştirildi. Çalışmanın son gününde fareler dekapite edilerek pankreas ve kan dokuları toplandı. Çalışmanın in vitro basamağında ise 1-2 günlük Wistar Albino cinsi sıçanlardan elde edilen dorsal kök gangliyonları (DKG) 24 saat yüksek glukoza maruz bırakıldı ve PNX-14'ün hücre canlılığına etkisi belirlendi. Elde edilen sonuçlar SPSS paket programında uygun istatistiksel yöntemler kullanılarak analiz edildi ve p<0.05 anlamlı kabul edildi. Bulgular: PNX-14 enjeksiyonunun farelerde DN grubuna kıyasla ağrı eşiğini arttırdığı (p<0.05), antioksidan ve antiinflamatuar etkinlik gösterdiği (p<0.05) ve pankreasın histolojik bütünlüğünü korumaya yardımcı olduğu belirlendi (p<0.0001). Ayrıca PNX-14'ün DKG'de hücre canlılığını arttırdığı tespit edildi (p<0.05). Sonuç: Streptozotosin kaynaklı DN'de, PNX-14 hem ağrı düzeylerini azaltmakta hem de oksidatif stres ve inflamasyonu modüle ederek pankreas dokusunu koruyucu etkiler göstermektedir. PNX-14'ün DN için potansiyel bir terapötik ajan olabilir. Anahtar Kelimeler: Diyabet, Diyabetik Nöropati, Dorsal Kök Gangliyonu, Phoenixin-14
Aim: Diabetes, a chronic metabolic disorder with impaired insulin function, can cause prolonged hyperglycemia leading to peripheral nerve damage and diabetic neuropathy (DN). This study evaluated the effects of the neuropeptide Phoenixin-14 (PNX-14) in experimental DN models. Material and Method: A total of 40 male Balb-c mice were divided into four groups: Control, DN, DN+PNX-14/50, and DN+PNX-14/100 (n=10). DN was induced in all groups except the control by a single intraperitoneal injection of streptozotocin (150 mg/kg) and monitored for 21 days. The control group received no treatment, while the DN group was administered physiological saline. PNX-14 was administered intraperitoneally at doses of 50 and 100µg/kg for 15 consecutive days in the DN+PNX-14 groups. During this period, nociceptive behaviors were evaluated using hot plate, tail flick, and von Frey tests. On the final day, mice were sacrificed, and pancreatic and blood tissues were collected. In the in vitro phase, dorsal root ganglion (DRG) neurons from 1–2-day-old Wistar Albino rats were exposed to high glucose for 24 hours, and the effect of PNX-14 on cell viability was assessed. Data were analyzed using SPSS, p<0.05 was considered statistically significant. Results: PNX-14 treatment significantly increased pain thresholds in DN mice (p<0.05), enhanced antioxidant and anti-inflammatory activity (p<0.05), and preserved pancreatic histological integrity (p<0.0001). PNX-14 improved cell viability in DRG cultures (p<0.05). Conclusion: In streptozotocin-induced DN, PNX-14 effectively reduced pain, modulated oxidative stress and inflammation, and protected pancreatic tissue. These findings suggest that PNX-14 may serve as a potential therapeutic agent for DN. Key Words: Diabetes, Diabetic Neuropathy, Dorsal Root Ganglion, Phoenixin-14
Aim: Diabetes, a chronic metabolic disorder with impaired insulin function, can cause prolonged hyperglycemia leading to peripheral nerve damage and diabetic neuropathy (DN). This study evaluated the effects of the neuropeptide Phoenixin-14 (PNX-14) in experimental DN models. Material and Method: A total of 40 male Balb-c mice were divided into four groups: Control, DN, DN+PNX-14/50, and DN+PNX-14/100 (n=10). DN was induced in all groups except the control by a single intraperitoneal injection of streptozotocin (150 mg/kg) and monitored for 21 days. The control group received no treatment, while the DN group was administered physiological saline. PNX-14 was administered intraperitoneally at doses of 50 and 100µg/kg for 15 consecutive days in the DN+PNX-14 groups. During this period, nociceptive behaviors were evaluated using hot plate, tail flick, and von Frey tests. On the final day, mice were sacrificed, and pancreatic and blood tissues were collected. In the in vitro phase, dorsal root ganglion (DRG) neurons from 1–2-day-old Wistar Albino rats were exposed to high glucose for 24 hours, and the effect of PNX-14 on cell viability was assessed. Data were analyzed using SPSS, p<0.05 was considered statistically significant. Results: PNX-14 treatment significantly increased pain thresholds in DN mice (p<0.05), enhanced antioxidant and anti-inflammatory activity (p<0.05), and preserved pancreatic histological integrity (p<0.0001). PNX-14 improved cell viability in DRG cultures (p<0.05). Conclusion: In streptozotocin-induced DN, PNX-14 effectively reduced pain, modulated oxidative stress and inflammation, and protected pancreatic tissue. These findings suggest that PNX-14 may serve as a potential therapeutic agent for DN. Key Words: Diabetes, Diabetic Neuropathy, Dorsal Root Ganglion, Phoenixin-14
Açıklama
Anahtar Kelimeler
Fizyoloji, Physiology
